- Home
- GENK vs BIVI Comparison
GENK vs BIVI Comparison
Compare GENK & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | BIVI |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 8.5M |
| IPO Year | 2023 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GENK | BIVI |
|---|---|---|
| Price | $1.93 | $1.39 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.67 | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 62.2K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,380,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $8.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.12 | N/A |
| 52 Week Low | $1.50 | $0.62 |
| 52 Week High | $5.57 | $9.09 |
Technical Indicators
Market Signals| Indicator | GENK | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 54.90 |
| Support Level | $1.58 | $1.14 |
| Resistance Level | $2.21 | $1.52 |
| Average True Range (ATR) | 0.20 | 0.10 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 54.57 | 62.53 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.